luminal

Dinoprost (Prostaglandin F2a) is a naturally occurring prostaglandin. It is used in medicine to induce labor and as an abortifacient.

Dinoprost tromethamine salt (PGF2α THAM) is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.

Diloxanide (RD3803) is an endomoeba insecticide. It is considered to be the luminal agent of choice for patients with mild enteroamoebiasis or asymptomatic cysts.

Tiliquinol (NSC-130828) (NSC-130828) is a non-absorbed luminal agent with anti-amoebic properties that is often used in conjunction with tibroquinol. It is commonly employed in the study and investigation of amebic liver abscesses.

Amiloride hydrochloride dihydrate (Amiloride HCl dihydrate) is a pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride hydrochloride dihydrate is used in conjunction with DIURETICS to spare POTASSIUM loss.

Ilaprazole sodium (IY-81149 sodium) , a substituted benzimidazole prodrug, is a selective and irreversible proton pump inhibitor. A weak base, Ilaprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.

Picolinafen is a pyridine herbicide that functions as an inhibitor of phytoene desaturase (PDS) and is utilized for its ability to manage the growth of broadleaf weeds by disrupting carotenoid biosynthesis. It exhibits cytotoxicity towards porcine trophoblast cells (pTr) and porcine luminal epithelial cells (pLE). By inducing the accumulation of reactive oxygen species (ROS), depleting calcium, and activating MAPK and PI3K signaling pathways, Picolinafen leads to reduced cell viability, increased apoptosis, impaired migration abilities, and altered expression of implantation-related genes, ultimately affecting the implantation capability of pTr cells. The LD50 value of Picolinafen for mammals is 2.7 mg/kg, and it is 7 μg/L for fish. Additionally, Picolinafen shows toxic effects during zebrafish embryonic development.

BACE-IN-1 acetate (BACE-IN-1 acetate (350228-37-4,Free base)) has been used as β-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE1) inhibitor in BACE1 inhibitor assay. β-Site amyloid precursor protein (APP) cleaving enzyme-1 (BACE1), an aspartic protease belongs to the protease family of enzymes comprises of six luminal cysteine residues. These residues help in the formation of three intermolecular disulfide bonds and N-linked glycosylation sites.

Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine (T20615) is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1

The growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) play major roles in enhanced smooth muscle cells growth in rodent blood vessels after vascular injury. Tyrosine kinase inhibition has been shown to be effective in blocking tyrosine phosphorylation at the PDGF and bFGF receptors in cultured fibroblast and vascular smooth muscle cells which in turn inhibits their proliferation[1]. CGP 53716 is a specific PDGFR tyrosine kinase inhibitor on SMC (smooth muscle cell) proliferation and migration in vitro and in neointimal formationin vivo[3]. CGP 53716 inhibited serum-induced cell growth in RASMC (rat aortic smooth muscle cells). And it completely blocked PDGF-BB tyrosine receptor autophosphorylation in RASMC and 3T3 cells, PDGF-BB-induced phosphorylation of mitogen-activated protein kinase at 1 μM in RASMC and inhibited PDGF-BB-induced c-Fos protein expression at 1 μM in RASMC; consistent with inhibition of PDGF-BB-induced DNA synthesis. Further, CGP 53716 inhibited PDGF-BB-, bFGF- and EGF-induced DNA synthesis in a concentration-dependent manner in each cell line. And it showed a 2- to 4-fold selectivity for PDGF-BB-stimulated DNA synthesis over bFGF or EGF in RASMC or 3T3 cells[1]. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-α and PDGFR-β. After rat carotid artery ballooning injuryin vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg/kg/day of CGP 53716 from 38 ± 10 (control group) to 4 ± 2. Intima/media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P=0.028) after rat aortic denudation[3].

NAA-004, also known as APAZA, has been shown to significantly inhibit toxin A-induced myeloperoxidase activity, luminal fluid accumulation, and structural damage to the colon in instances of toxin A-induced colitis.

BAY-5094, a PPAR gamma (PPARG) inverse agonist, exhibits oral activity and is applicable in luminal bladder cancer research [1].

BAY-9683 is a covalent PPARG inverse agonist that is orally active. It is relevant for research into conditions characterized by excessive PPARG activity, including luminal bladder cancer [1].

G-Pen-GRGDSPCA TFA is an αvβ3 inhibitory RGD peptide. It inhibits neointimal hyperplasia and luminal narrowing following vascular injury and regulates the migration and proliferation of smooth muscle cells. This compound can be utilized in studies related to mechanisms of vascular injury repair.